

SILYMARIN INDUCES GLUCAGON LIKE PEPTIDE-1 SECRETION AND INCREASES ITS RECEPTOR GENE EXPRESSION IN PANCREATIC TISSUE IN PARTIALLY PANCREATECTOMIZED RATS

^{1*}Claudia Soto, ¹Imelda González, ²Luis Raya, ³Ulises Carrasco, ¹Luz Tovar

¹Departamento de Sistemas Biológicos, Universidad Autónoma Metropolitana Xochimilco, Ciudad de México, México.

²Hospital de Especialidades, Instituto Mexicano del Seguro Social. Cancún, México

³Departamento de Biotecnología. Universidad Autónoma Metropolitana-Iztapalapa, Ciudad de México, México

Abstract- Glucagon-like peptide-1 (GLP-1) is an incretin produced and released by gut endocrine L-cells in response to the ingestion of carbohydrates, lipids and proteins. It is also produced in the pancreatic tissue, both in humans and rats. In the pancreatic tissue, GLP-1, stimulates insulin secretion in β -cells, induces neogenesis, proliferation, differentiation and maintenance of β cell mass, and inhibits apoptosis of these cells. For these reasons, this peptide has been used in the management of type 2 diabetes mellitus (DM) and has also been tried in type 1 DM. The action of GLP-1 on β cells is initiated through binding with a GLP-1 membrane bound receptor (GLP-1R), coupled to G protein, which leads to a rise in cyclic AMP (cAMP) and calcium levels, followed by insulin secretion. It was reported that GLP-1 induces an increase of PDX-1 gene expression levels and enhances the transcription of the insulin gene by increasing the binding of PDX-1 transcription factor to the insulin gene promoter region. We reported previously that silymarin induces both PDX-1 transcription factor and the insulin gene expression, as well as β -cell proliferation in pancreatic tissue. In this study we demonstrated that silymarin treatment to partially pancreatectomized rats increases pancreatic: GLP-1R gene expression, tissue immunoreactivity for GLP-1, densitometry of this peptide for Western blot analysis, proliferation of GLP-1 secreting cells, insulin serum concentration and a decrease in glucose serum. All these tests were performed to show the contrast with untreated pancreatectomized animals. Our results may suggest that silymarin increases the secretion of pancreatic GLP-1, and its activity. It would seem that it may be related to the increase in the PDX-1 transcription factor previously reported in silymarin treatment of partially pancreatectomized rats.

Keywords— proliferation of pancreatic GLP-1 producing cells, GLP-1 pancreatic receptor, GLP-1R, GLP-1 pancreatic immunoreactivity

I. INTRODUCTION

Glucagon-like peptide-1 (GLP-1), is produced and released by gut endocrine L-cells located predominantly in the distal small intestine and colon, in response to the ingestion of carbohydrates, lipids and proteins [1]. Some authors have reported that GLP-1 may also be produced in the pancreatic islets, both in human [2,3] and rat pancreas [4] residing in α -cells [5]. GLP-1 is a product of post-translational cleavage of pro-glucagon peptide [6, 7]. At the pancreatic level, GLP-1 stimulates insulin secretion in β -cells in a dependent blood glucose concentration [8], induces differentiation, neogenesis, proliferation, and plays a role in the long-term maintenance of β cell mass by inhibiting apoptosis of these cells, both in human and in animal models [9, 10]. GLP-1 also suppresses α -cell glucagon secretion, increases δ -cell somatostatin, delays gastric emptying and reduces appetite [11]. For these reasons, therapies based on this peptide have been used in the management of type 2 diabetes mellitus [12, 1] and in some studies it have been reported that this treatment has been tried on type 1 DM [13]. The action of GLP-1 on β -cells is initiated through binding to the GLP-1R

membrane bound receptor, which is coupled to G protein [14, 15]. The activation of GLP-1R leads to a rise in cyclic AMP (cAMP) and calcium levels followed by insulin secretion. In this process, GLP-1R enhances the inhibition of ATP-sensitive potassium channels (K⁺ATP) [16] and facilitates the Ca²⁺ influx and stimulation of insulin exocytosis [17]. The principal effectors of this cAMP mechanism are creatin phosphokinase A, (PKA) and exchange protein directly activated by cAMP2 (EPAC2). GLP-1 both in vitro and in vivo enhances insulin gene transcription by the increase of the binding PDX-1 transcription factor to the insulin gene promoter region [18, 19, 20, 21]. Pancreatic duodenal homeobox 1 (PDX-1) is considered to be the key transcription factor involved in early pancreatic development, the expression, differentiation and maintenance of the mature β -cells [22]. PDX-1 is a key regulator of insulin gene expression. Also by cAMP response element-binding protein (CREB) which after activating GLP-1R binds to cAMP responsive element (CRE) localized in the insulin gene promoter region [23]. All these actions contribute to β -cell mass. However, it was reported that the effect of GLP-1 on

Publication History

Manuscript Received : 29 April 2017
Manuscript Accepted : 20 May 2017
Revision Received : 22 June 2017
Manuscript Published : 30 June 2017

pdx-1 promoter region activity is short lived and that only stimulates this activity for about 2-3 hours. In a previous report, we showed that silymarin induces both PDX-1 and the insulin gene expression as well as proliferation of β -cells in pancreatic tissue [24]. Silymarin is a standardized extract of *Silybum marianum*, which has demonstrated certain properties in hepatic disorders of different etiology, such as, regenerative, antioxidant, anti-inflammatory and anti-fibrotic [25]. This study shows that silymarin treatment to partially pancreatectomized rats increases pancreatic GLP-1R expression, GLP-1 tissue immunoreactivity, densitometry of this peptide for Western blot analysis, proliferation of GLP-1 secreting cells, insulin serum concentration and a decrease in glucose serum, compared to the control group of untreated partially pancreatectomized animals. Our results, may suggest that silymarin increases the production of GLP-1 and its activity, which in turn, may be related to the increase of GLP-1R and the increase in the actions of the PDX-1 transcription factor, previously reported for the silymarin treatment of partially pancreatectomized rats [24].

II. METHODS

Silymarin and all reagents were obtained from Sigma Chemical Co. (St. Louis, MO., USA), Promega (Madison, WIS), Bio Rad (Bio Rad Laboratories Inc.) or from local suppliers (Merck and J.T. Baker, México) and were of analytical grade. Testing and experiments performed in this study followed the guidelines stated in "Principles of Laboratory Animal Care" (NIH publication #85-23, revised 1985) and Mexican regulations "Norma Oficial Mexicana NOM-062-ZOO-1999, Especificaciones técnicas para la producción, cuidado y uso de animales de laboratorio" (published in December, 1999). The studies were approved by the committee of ethics of the Biological Sciences Division Council in our University.

A. Animal treatment

Male Wistar rats (200-220 g of b. wt.) were obtained from our animal facility, fed with Purina standard chow, and maintained at 20-22°C with 12-h cycles of light/dark. The animals were divided into the following groups: 1.- Pancreatectomy group: 36 rats were anesthetized with ketamine (50 mg/Kg) and xylazine (5 mg/Kg). 60% of pancreatic tissue was removed by cotton applicators rubbed gently. These animals in turn were divided into 6 groups for the following sacrifice times: 3, 7, 14, 21, 42 and 63 days after pancreatectomy. Three animals from each group were administered with 5-bromo-2'-deoxyuridine (BrdU) (50 mg/Kg b.w. i.p.), 18 hours before sacrifice to assess the proliferation of GLP-1 secreting cells. Their body weight and serum glucose were measured weekly for each fasted rat. 2.- Pancreatectomy + silymarin: The same schedule was followed as with group 1. Pancreatectomized animals were administered with silymarin daily (200 mg/Kg b.w. p.o.) n=36. 3.- Control: These animals underwent a sham surgery and were sacrificed before treatments began (n=6). Each week, animals were fasted for 7 hours. Blood glucose was measured with an automatic glucometer (Abbot Diabetes Care Ltd. U.K.) in the tail vein and its weight was registered.

B. Blood and tissue collection

Animals were anesthetized for sacrifice with sodium pentobarbital (50 mg/Kg b.w., i.p.). Blood was obtained through cardiac puncture. The pancreas was extracted by dissecting the abdominal cavity and removing fat tissue.

C. RNA isolation and RT-PCR assay for GLP-1R

RNA was isolated from a fragment of the pancreatic tissue (50 mg) of each animal under the different experimental conditions described above and was prepared using the column method according to the manufacturer's protocol PROMEGA (Madison, WI). Briefly, the tissue was homogenized in 1000 μ L of lysis buffer. 350 μ L of dilution buffer was added to 175 μ L of lysate. The sample was heated at 70°C for 3 minutes and centrifuged for 10 minutes. 250 μ L of 95% ethanol was added to clear lysate and mixed. The lysate was transferred to column and centrifuged for 1 minute. 600 μ L of wash solution was added and centrifuged for 1 minute. 50 μ L of DNase was applied to column and incubated for 15 minutes at room temperature. After this time, 200 μ L of DNase stop solution was added and centrifuged for 1 minute and washed twice. To eluate the RNA, 100 μ L of nuclease free water was added to membrane. RT-PCR was performed with 2 μ g of RNA for the target gene and the 18s ribosomal constitutive gene for semi-quantitation. Oligonucleotide primers were designed based on literature sequences: 5' -CAG AAG TTG GTC GTG AGG CA-3' sequence for the sense (5') primer and the 5' -GCC TTT CAC CAG CCA AGC AA-3' for the anti-sense (3') primer for GLP-1R and, 5' -GTA ACC CGT TGA ACC CCA TT-3' for sense (5') and 5' -CAA TCC AAT CGG TAG TAG CG-3' for the anti-sense (3') primer for ribosomal 18s mRNA amplification. Amplification was initiated for 5 min at 94 °C, followed by 35 cycles of 95 °C, 60 °C and 72 °C, for 1 min for each step, and reaction products were sequence-verified. Products were separated on a 2% agarose gel followed by ethidium bromide staining and densitometry analysis using a Kodak EDAS 290 (Kodak, USA).

D. Serum insulin and glucose levels

At the end of treatments, the serum insulin levels were measured for each animal with High Rate Insulin ELISA (Mercodia, Uppsala, Sweden) according to the manufacturer's protocol. Glucose serum levels were determined (each week) by means of a glucometer (Optium, Abbott, Diabetes Care Ltd. U.K.) on each fasted animal's tail.

E. GLP-1 secreting cells proliferation assessment

Fragments of the pancreatic tail were fixed in 4% paraformaldehyde in PBS and embedded in paraffin. Five μ m-thick sections were obtained, deparaffinized and a double label immunohistochemistry was carried out to assay the proliferation of the GLP-1 secreting cells. The primary and secondary antibodies of this study were obtained from Zymed Labs, Inc. (San Francisco). Prior to immunolabelling, deparaffinized pancreatic 5 μ m-thick sections were immersed in 70% ethanol for 10 min. and rinsed with PBS. 0.3% H₂O₂ for 10 min. was added and incubated in 0.5% IgG-free albumin in phosphate buffered saline (PBS) for 30 min. For GLP-1 immunoreaction, sections were labeled with mAbs anti-GLP (1:100) for 1 hour at 30°C. HRP-rabbit anti-goat IgG (1:50) (peroxidase conjugated secondary antibody) was added for 2 hours at room temperature. 600 μ L DAB

(diaminobenzidine)/ H₂O₂ for 8 min, was used to visualize the reaction. Sections were rinsed with PBS. For BrdU immunoreaction, these sections were treated with 0.3% H₂O₂ for 10 min and were immunolabelled with mAbs anti-BrdU (1:100) at room temperature for 2 hours. HRP-goat anti-mouse IgG (1:50) was added for 90 min. at room temperature. A mixture of NiCl₂ (1%) + CoCl₂ (1%) was added to DAB/ H₂O₂ solution for color development for 8 min. Then sections were counterstained with hematoxylin. Double immunolabel was seen in black color. Sections were analyzed with a 40X objective. The total number of cells and double immunolabelled cells were counted in five tissue areas with a Leica Application Suite program on a Leica DM 1000 microscope.

F. Pancreatic tissue GLP-1, glucagon double immunoassay

In order to prove GLP-1 secretion in α -pancreatic cells, a glucagon, GLP-1 double immunoassay was made for the first double immunolabel as described above (2.5 section). mAbs anti-GLP-1 (1:100) was utilized as a primary antibody and HRP-rabbit anti-goat IgG (1:75) as a secondary antibody. As a primary antibody mAbs anti-glucagon (1:75) was used for double immunostaining α -pancreatic cells and HRP- goat antirabbit IgG (1:100) as a secondary antibody. Double-immunolabelled sections were analyzed with a DM-1000 Leica microscope.

G. Western blot analysis

To determine the level of pancreatic GLP-1, a fragment (40 mg) of this tissue was homogenized in 10 mL of an ice-cold isolation solution (250 mM sucrose, 10 mM triethanolamine, 1 mg/mL leupeptin, and 1 mg/mL phenylmethylsulfonyl fluoride, pH 7.6) at 15,000 rpm with 3 strokes per 15 sec with a tissue homogenizer (IKA Works, Inc. Wilmington, NC). After homogenization, total protein concentrations were measured using the Bradford protein assay (Bio-Rad Laboratories Inc., Hercules, CA). Samples were stabilized by adding 1 vol of 2X Laemmli sample buffer to 1 vol of sample, and heated at 70°C for 10 min. 100 µg of protein from each sample were loaded into individual lanes and electrophoresed on 12.5% polyacrylamide-SDS minigels using a Mini-PROTEAN Tetra Cell electrophoresis apparatus (Bio-Rad Laboratories Inc.). The proteins were then transferred electrophoretically to PVDF membrane (Immobilon-P, Millipore, Billerica, MA, USA). After blocking with 5% skim milk in PBS-T (80 mM Na₂HPO₄, 20 mM NaH₂PO₄, 100 mM NaCl, and 0.2% Tween-20, [pH7.5]) for 1 hour, the membranes were probed overnight with mAbs anti-GLP-1 as a primary antibody at 4°C (1:500) (Zymed Labs, Inc, San Francisco) and then incubated with secondary horseradish peroxidase conjugated antibody (1:1000) (Zymed Labs, Inc, San Francisco). Antigen-antibody reactions were viewed using enhanced chemiluminescence substrate (Immobilon Western, Millipore, Billerica, MA, USA) and analyzed in Chemidoc XRS (Bio-Rad, Laboratoties, Inc) with the Quantity One 1-D Analysis v4.6.5 image processing software (Bio-Rad).

H. Statistical methods.

ANOVA followed by Tukey and Dunnet tests were used to compare experimental and control groups (SPSS, Chicago, IL, USA) with significance at p < 0.05.

III.RESULTS

A. GLP-1R pancreatic gene expression

Figure 1 shows the gene expression of GLP-1 receptor (GLP-1R). Pancreatectomized untreated animals (Figure 1a) showed variability at different times. In contrast, silymarin induced a significant increase in this receptor at all times throughout the treatment (except on day 21) (Figure 1b), in comparison of untreated pancreatectomized animal groups at the same times. According to this result, silymarin treatment produced an increase in gene expression of PDX-1 transcription factor and insulin in pancreatectomized rats [24], as previously reported.

B. Proliferation of GLP-1 secreting pancreatic cells

GLP-1 and BrdU double immunolabelled cells were counted as a percentage of the total number of cells in each field of five in each animal in each experimental group, Figure 2. In both groups, treated and untreated, an increase in the number of GLP-1 secreting cells was observed during the time course of the assay from 14 to 63 days. It became evident that silymarin treatment induced a significant increase in the number of these cells during this period of time in the treated groups in comparison to untreated groups. Representative photomicrographs of the double immunolabelled cells with GLP-1 and BrdU are shown in Figure 3. It may be observed in these photomicrographs that there are more double immunolabelled cells in the groups treated with silymarin.




Figure 1. GLP-1 receptor (GLP-1R) gene expression. (A) pancreatectomized untreated group. (B) pancreatectomized group treated with silymarin. (C) control group. Each bar represents the mean ± S.E.M. * p < 0.05 versus other times of

the same group. + $p < 0.05$ treated versus untreated animals at the same times. $n = 5$.




Figure 2. Proliferation of GLP-1 secreting cells. These were counted as percentage of total cells in each field of five fields in each animal pancreatic tissue at different times after pancreatectomy: (A) untreated; (B) silymarin treated; (C) control group. Each bar represents the mean \pm S.E.M. * $p < 0.05$ versus other times of the same group. + $p < 0.05$ treated versus untreated animals at the same times. $n = 5$.




Figure 3. Double immunolabelling for GLP-1 and BrdU. Photomicrographs of double immunolabelled cells of pancreatic tissue (arrows) ($\times 400$ magnification). Scale bar = $25 \mu\text{m}$. (A) untreated group; (B) group treated with silymarin. Both at 63 days after pancreatectomy; (C) control group.

C. GLP-1, glucagon double immunolabelled pancreatic tissue cells

These double immunolabels for glucagon and GLP-1 in the pancreatic tissue of some experimental groups are shown in Figure 4. These photomicrographs indicate that this GLP-1 peptide is produced in α -pancreatic cells, as has been reported. These double immunolabels were not counted but it may be appreciate a greater number of double immunolabelled cells in the treated groups.

D. GLP-1 Western blot analysis

This analysis shows GLP-1 pancreatic peptide at 2 and 9 weeks of the treatment. The level of this peptide was increased in the groups of pancreatectomized animals treated with silymarin. This increase was greater in the group treated for nine weeks than in the other groups (Figure 5).





Figure 4. Double immunolabelling for GLP-1 and glucagon. Photomicrographs of double immunolabelled cells of pancreatic tissue (arrows) ($\times 400$ magnification). Scale bar = $25 \mu\text{m}$. (A) untreated group; (B) group treated with silymarin. Both at 63 days after pancreatectomy; (C) control group.

Figure 5. Representative Western blot analysis of



pancreatic GLP-1 peptide and β -actin of partially pancreatectomized rats. (A, C) untreated group and (B, D) group treated with silymarin. Where (A, B) is at 14 days and (C, D) is at 63 days after pancreatectomy.

E. Serum insulin and glucose levels

Serum insulin levels are shown in Table 1, showing a variation in values in respect to the control group (1.15 ± 0.02 mM/L). These values were higher in the groups treated with silymarin (except day 7). Table 2 shows glucose serum levels. At all times after pancreatectomy, the serum glucose levels of untreated animal groups were maintained over the control value group (5.7 ± 0.005 mM/L). Silymarin treatment produced a significant decrease of serum glucose levels in respect to the untreated group for the same time after pancreatectomy. These results could be related to the insulin serum levels of the silymarin treated groups.

Table 1. Serum insulin levels (ng/mL) in experimental groups

Days after pancreatectomy	Untreated group	Silymarin treated group
Control	1.15 ± 0.02	1.15 ± 0.02
3	$0.250 \pm 0.079^*$	0.687 ± 0.125
7	1.10 ± 0.45	0.600 ± 0.023
14	$0.333 \pm 0.077^*$	$0.575 \pm 0.02^*$
21	$0.18 \pm 0.38^*$	$0.84 \pm 0.212^+$
42	1.200 ± 0.252	$2.81 \pm 0.222^{**}$
63	1.143 ± 0.37	$3.245 \pm 0.25^{**}$

Each value represents the mean \pm S.E.M. * $p < 0.05$ versus other times of the same group; + $p < 0.05$ treated versus untreated animals at the same times. $n = 5$.

Table 2. Serum glucose levels mM/ L in experimental groups

Days after pancreatectomy	Untreated group	Silymarin treated group
Control	$5.7 \pm 0.005^*$	5.7 ± 0.005
3	8.98 ± 1.685	8.05 ± 0.201
7	8.00 ± 0.5000	$6.5 \pm 0.141^+$
14	9.80 ± 0.738	$7.0 \pm 0.252^+$
21	7.74 ± 0.200	8.00 ± 1.0
42	10.65 ± 0.865	$7.15 \pm 0.356^+$
63	9.54 ± 0.467	$6.20 \pm 0.155^+$

Each value represents the mean \pm S.E.M. + $p < 0.05$ treated versus untreated animals at the same times. $n = 5$.

IV. DISCUSSION

It is well documented that some of the more important GLP-1 effects are the induction of β -cell neogenesis [26]. This peptide plays an important role for the long-term maintenance of β cell mass, which contributes 80% to glucose homeostasis [27]. It has been proposed that the majority of GLP-1 effects are transduced by a single GLP-1 receptor, cloned from pancreatic β -cells [15]. De León et al.

[28] reported that in CD-1 mice with inactivated gene of GLP-1R ($glp-1R^{-/-}$) after pancreatectomy, showed a significant defect in β -cell mass regeneration. Yazhou et al. [29] reported in isolated rat β -cells that GLP-1 receptor signaling reduced apoptosis induced by cytokines. These findings demonstrate the importance of GLP-1 receptor for activating this peptide. Our results show that silymarin treatment significantly increased the gene pancreatic expression of this receptor, which may increase the binding of GLP-1 with its receptor and therefore the actions of the peptide. Despite the short-time action of GLP-1, there are some therapies based on the use of GLP-1 in the management of type 2 diabetes mellitus [12, 1], as exendin-4, which is an agonist of GLP-1 and is active for a longer period of time. In a model of partial pancreatectomy, the administration of exendin-4 for 10 days after surgery produced a stimulation of pancreatic regeneration, and an expansion of β -cell mass by the neogenesis and proliferation of these cells with attenuated pancreatectomy hyperglycemia [30]. This author showed that exendin-4, stimulates both the differentiation of β cells from ductal progenitor cells (neogenesis) and proliferation of these β cells in a partial pancreatectomy rat model of type 2 diabetes mellitus, inducing the regeneration of the pancreas and β cell mass.

In this study we demonstrated that, in addition to the increase of GLP-1R gene expression induced by silymarin, the treatment with this compound to partially pancreatectomized rats, induced an increase of immunoreactivity for GLP-1 in pancreatic tissue (Figure 3), an enhanced pancreatic tissue level of this peptide (Figure 5), an increase in the proliferation of pancreatic GLP-1 secreting cells (Figure 2), an increase in insulin blood levels (Table 1) and therefore, a decrease in blood glucose levels (Table 2). The effects reported for this peptide are in accordance with those in the bibliography and were higher in treated than in untreated animals. This may suggest that the increase in these effects may be related to the silymarin treatment on the GLP-1 secretion, since there was an increase in the results observed. Wideman et al. [31] showed that by inducing GLP-1 secretion directly within pancreatic islets by means of PC1/3 (prohormone convertase that produces GLP-1 from α -cell glucagon) through adenovirus-mediated expression in these cells, increases GLP-1 secretion, improving glucose-stimulated insulin secretion, possibly by enhancing nuclear PDX-1 transcription factor and insulin content of islet β cells. It was reported that the GLP-1 analog, exendin-4, enhances the pancreatic expression of PDX-1 transcription factor, which plays a critical role in pancreas development, differentiation, maintenance of β pancreatic cells and plays a key role in insulin gene expression [32], thereby stimulating β cell neogenesis and increasing islet size [21]. Campbell et al. [33] examined the effect of GLP-1 on pdx- promoter activity in the cell line Min 6. When these cells were stimulated with GLP-1 (10 nM) at low concentrations of glucose, an increase in transcriptional activity was observed with the full length pdx-1 promoter region compared to low glucose alone. When the pdx promoter region was stimulated with GLP-1 at high glucose concentrations, there was a further increase in transcriptional activity, which evidenced that GLP-1 positively regulates the promoter region of pdx-1 gene activity and stimulates the mRNA levels of PDX-1, increasing the PDX-1 protein both in vitro and in vivo [34,

35, 36]. This may induce an increase in binding the PDX-1 protein to the insulin gene promoter region. PDX-1 regulates the insulin gene expression [34, 37] and causes an increase in insulin mRNA levels. This could explain the GLP-1 pancreatic activity in the induction of neogenesis and maintenance of β cell mass. We previously reported that silymarin increased the gene expression of the transcription factor PDX-1, its tissular immunoreactivity and β cell proliferation [24]. The previously described findings in this section may suggest that silymarin induces the increase of GLP-1 secretion and its effects. The results obtained in this study suggest that it may involve an increase in the gene expression of the transcription factor PDX-1, its tissular immunoreactivity, β pancreatic cell proliferation and an increase in blood insulin levels [24].

Through the analysis of mice with specifically inactivated *pdx-1* gene in β -cells (β -cell*pdx1*^{-/-} mice), Yazhou et al. [38] demonstrated that PDX-1 is essential in β -cells for the regulatory, proliferative and cytoprotective actions of GLP-1. Studies by these authors demonstrate that exendin-4 induces a decrease in glucose blood levels after a glucose challenge, an increase in plasma insulin, pancreatic insulin content and glucose-stimulated insulin secretion in islets of mice with β cells *pdx-1*^{+/+} but not in mice *pdx-1*^{-/-}. Also, exendin-4 significantly increased β cell proliferation, reduced apoptosis and increase the levels of insulin mRNA transcripts in mice with β cells *pdx-1*^{+/+} but not in mice with *pdx-1*^{-/-}. These findings demonstrate that PDX-1 gene expression is essential for the integration of GLP-1R dependent signals for the GLP-1 secretion from α cells and for the activity of this peptide on β cells. In turn, GLP-1 enhances the pancreatic gene expression of PDX-1, which overall may suggest a necessary coordination between GLP-1, GLP-1R and PDX-1 for correct activity of GLP-1.

Furthermore, Lotfy et al. [26] showed that GLP-1 treatment of normal and diabetic rats significantly increases the pancreatic antioxidant enzymes, catalase and glutathione reductase, which contribute in protecting β cells from free radicals that might kill the cells since they are particularly susceptible to attack by free radicals. We also reported [39] that silymarin increases the effect and activity of pancreatic antioxidant enzymes: catalase, glutathione peroxidase and superoxide dismutase. We may suggest by the Lotfy et al. [26] studies that the increase of expression and activity of these enzymes were induced by GLP-1, which as we have pointed out is increased by silymarin treatment and therefore could prevent the death of β cells.

V. CONCLUSION

In conclusion, the results of our study indicated that the application of the silymarin treatment induced an increase of GLP-1R gene expression and GLP-1 secretion in pancreatic tissue. Since this peptide enhances the PDX-1 pancreatic expression and its transcription factor's activity, observed in our previous studies with this compound [24]. This indicates that silymarin should be considered a compound potentially useful in the treatment of diabetes mellitus.

Acknowledgments. We are indebted with Miss Mónica Guzmán and Gabriela Ramírez for their excellent technical assistance at the performing the Western blot analysis.

CONFLICTS OF INTEREST

The authors declare no conflict of interest

REFERENCES

- [1] Marathe C, Rayner C, Jones K, Horowitz M. Glucagon like peptides 1 and 2 in health and disease: A review. *Peptides* 2013;424:75-86.
- [2] Uttenthal L, Ghiglione M, George S, Bisho E, Polak J, Bloom S. Molecular forms of glucagon-like peptide-1 in human pancreas and glucagonomas. *J Clin Endocrinol Metab* 1985;61:472-479.
- [3] Varndell I, Bishop A, Sikri K, Uttenthal L, Bloom S, Polack J. Localization of glucagon-like peptide (GLP) immunoreactants in human gut and pancreas using light and electron microscopic immunocytochemistry. *J Histochem Cytochem* 1985;33:1080-1086.
- [4] Mojsov S, Kopezynski M, Habener J. Both amidated and nonamidated forms of glucagon-like peptide 1 are synthesized in the rat intestine and the pancreas. *J Biol Chem* 1990;265:8001-8008.
- [5] Marchetti P, Lupi R, Bugliani M, Kirkpatrick C, Sebastian G, Grieco F, Del Guerra S, D' Aleo V, Piro S, Marselli L, Boggi U, Filippini F, Tinti L, Salvani, Woolheim C, Purrello F, Dotta F. A local glucagon-like peptide 1 (GLP-1) system in human pancreatic islets. *Diabetologia* 2012;55:3262-3272.
- [6] Fehmann HC, Göke R, Göke B. Cell and molecular biology of the incretin hormones glucagon-like peptide-1 and glucose-dependent insulin releasing polypeptide. *Endocr Rev* 1995;16:390-410
- [7] Zhang F, Tang X, Cao H, Lü Q, Li N, Liu Y, Zhang X, Zhang Y, Cao M, Wan Y, An Z, Tong N. Impaired Secretion of Total Glucagon-like Peptide-1 in People with Impaired Fasting Glucose Combined Impaired Glucose Tolerance. *Int Jour Med Sci* 2012;9:574-581
- [8] Mojsov S, Weir, G, Habener J. Insulinotropin: glucagon-like peptide 1 (7-37) co-encoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas. *J Clin Invest* 1987;79:616-619.
- [9] Drucker D. Glucagon like peptides: regulators of cell proliferation, differentiation and apoptosis. *Mol Endocrinol* 2003;17:161-171.
- [10] Buteau J. GLP-1 receptor signaling: effects on pancreatic cell proliferation and survival. *Diab. Metab* 2008;34(Supl 2):S73-77.
- [11] Rondas D, D' Hertog L, Overbergh L, Mathieu C. Glucagon-like peptide-1: modulator of β -cell dysfunction and death. *Diabetes, Obesity and Metabolism* 2013;15 (Suppl.3):185-192.
- [12] Girard J. The incretins: From the concept to their use in the treatment of type 2 diabetes. Part A: Incretins concept and physiological function. *Diab Metab* 2008;34:550-559.
- [13] Kielgast U, Holst J, Madsbad S. Antidiabetic actions of exogenous and endogenous GLP-1 in type 1 patients with and without residual beta-cell function. *Diabetes* 2011;60:1599-607.
- [14] Drucker D, Philippe J, Mojsov S, Chick W, Habener J. Glucagon-like peptide 1 stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line. *Proc Natl Acad Sci USA* 1987;84:3434-3438.
- [15] Thorens B. Expression and cloning of the pancreatic beta cell receptor for the gluco-incretin hormone glucagon-like peptide 1. *Proc Natl Acad Sci USA*, 1992;89:8641-8645.
- [16] Kang G, Leech C, Chepurny O, Coetzee W, Holz G. Role of the cAMP sensor Epac as a determinant of K-ATP channel ATP sensitivity in human pancreatic beta cells and rat INS-1 cells. *J Physiol* 2008;586:1307-1319.
- [17] Gromada J, Bokvist K, Ding W, Holst J, Nielsen J, Rorsman P. Glucagon-like peptide 1 (7-36) amide stimulates exocytosis in human pancreatic beta-cells by both proximal and distal regulatory steps in stimulus-secretion coupling. *Diabetes* 1998;47:57-65.
- [18] Wang J, Egan M, Raigad O, Nativ J, Roth C, Montrose R. Glucagon-like peptide-1 affects gene transcription and messenger

- ribonucleic acid stability of components of the insulin secretory system in RIN1046-38 cells. *Endocrinology* 1995;136:4910-4917.
- [19] Wang X, Cahill C, Pineyro M, Zhou J, Doyle M, Egan J. Glucagon-like peptide-1 regulates the beta cell transcription factor PDX-1 in insulinoma cells. *Endocrinology* 1999;140:4904-4970.
- [20] Perfetti R, Zhou J, Doyle M, Egan J. Glucagon-like peptide-1 induces cell proliferation and pancreatic-duoden homeobox-1 expression and increases endocrine cell mass in the pancreas of old glucose-intolerant rats. *Endocrinology* 2000;141:4600-4605.
- [21] Stoffers D, Kieffer T, Hussain M, Drucker D, Bonner-Weir S, Habener J, Egan J. Insulinotropic glucagon-like peptide-1 agonists stimulate expression of homeodomain protein IDX-1 and increase islet size in mouse pancreas. *Diabetes* 2000;49:741-748.
- [22] Chakrabarti S, James J, Mirmira R. Quantitative assessment of genotargeting in vitro and in vivo by the pancreatic transcription factor, Pdx 1. Importance of chromatin structure in directing promoter binding. *J Biol Chem* 2000;277:13286-13293.
- [23] Dalle S, Quoyer J, Varin E, Costes S. Roles and regulation of the transcription factor CREB in pancreatic beta-cells. *Curr Mol Pharmacol* 2011;4:187-195.
- [24] Soto C, Raya L, Juárez J, Pérez J, González I. Effect of Silymarin in Pdx-1 expression and the proliferation of pancreatic β -cells in a pancreatectomy model. *Phytomedicine* 2014;21:233-239.
- [25] Abenavoli L, Caspasso R, Milic N, Caspasso F. Milk thistle in liver diseases: past, present, future. *Phytother Res* 2010;24:1423-1432.
- [26] Lotfy M, Singh J, Rashed H, Tariq S, Zilahi, Adeghate E. The effect of glucagon-like peptide-1 in the management of diabetes mellitus: cellular and molecular mechanisms. *Cell Tissue Research* 2014;358:343-358.
- [27] Vetter M, Cardillo S, Rickels M, Iqbal N. Narrative review: effect of bariatric surgery on type 2 diabetes mellitus. *Ann Intern Med* 2009;150:94-103.
- [28] De León D, Deng S, Madani R, Ahima R, Drucker D, Stoffers D. Role of endogenous glucagon-like peptide-1 in islet regeneration after partial pancreatectomy. *Diabetes* 2003;52:365-371.
- [29] Yazhou L, Hansotia T, Yusta B, Ris F, Halban P, Drucker D. Glucagon-like peptide-1 receptor signaling modulates beta cell apoptosis. *J Biol Chem* 2003;278:471-478.
- [30] Xu G, Stoffers D, Habener J, Bonner-Weir S. Exendin-4 stimulates both β -cell replication and neogenesis, resulting in increased β -cell mass and improved glucose tolerance in diabetic rats. *Diabetes* 1999;48:2270-2276.
- [31] Wideman R, Yu I, Webber T, Verchere B, Johnson J. Improving function and survival of pancreatic islets by endogenous production of glucagon-like peptide 1 (GLP-1). *Proc Natl Acad Sci* 2006;103:13468-13473.
- [32] Babu D, Deering T, Mirmira R. A feat of metabolic proportions: Pdx1 orchestrates islet development and function in the maintenance of glucose homeostasis. *Mol Genet Metab* 2007;92:43-55.
- [33] Campbell S, Macfarlane W. Regulation of the pdx1 gene promoter in pancreatic β -cells. *Biochem Biophys Res Comm* 2002;299:277-284.
- [34] Wang Q, Li L, Xu E, Wong V, Rhodes C, Brubaker P. Glucagon-like peptide-1 regulates proliferation and apoptosis via activation of protein kinase B in pancreatic (INS-1) beta cells. *Diabetologia* 2004;47:478-487.
- [35] Shiota C, Larsson O, Shelton K, Shiota M, Efanov A, Hoy M, Lindner J, Koopitwut S, Juntti-Bergen L, Gromada J, Berggren P, Magnuson M. Sulfonylurea receptor type 1 knock-out mice have intact feeding-stimulated insulin secretion despite marked impairment in their response to glucose. 2004. *J Biol Chem* 2002;277:37176-37183.
- [36] Gauthier B, Brun T, Sarret E, Ishihara H, Schaad O, Descombes P, Wollheim C. Oligonucleotide microarray analysis reveals PDX1 as an essential regulator of mitochondrial metabolism in rat islets. *J Biol Chem* 2004;279:31121-31130.
- [37] Iype T, Francis J, Garmey J, Schisler J, Nesher R, Weir G, Becker T, Newgard C, Griffen S, Mirmira R. Mechanism of insulin gene regulation by the pancreatic transcription factor Pdx-1: application of pre-mRNA analysis and chromatin immunoprecipitation to assess formation of functional transcriptional complexes. *J Biol Chem* 2005;280:16798-16807.
- [38] Yazhou L, Cao X, Li L, Brubaker P, Hedlund H, Drucker D. β -cell Pdx1 expression is essential for the regulatory, proliferative, and cytoprotective actions of glucagon-like peptide-1. *Diabetes* 2005;54:482-491.
- [39] Soto C, Recoba R, Barrón H, Álvarez C, Favari L. Silymarin increases the pancreatic activity of antioxidant enzymes in alloxan-induced diabetes mellitus in the rat. *Comp Biochem. Physio* 2003;136C:205-212.